Alnylam Pharmaceuticals Inc (ALNY)vsWestern Digital Corporation (WDC)
ALNY
Alnylam Pharmaceuticals Inc
$303.05
-0.19%
HEALTHCARE · Cap: $37.76B
WDC
Western Digital Corporation
$575.50
+4.79%
TECHNOLOGY · Cap: $225.26B
Smart Verdict
WallStSmart Research — data-driven comparison
Western Digital Corporation generates 175% more annual revenue ($11.78B vs $4.29B). WDC leads profitability with a 55.3% profit margin vs 12.6%. ALNY appears more attractively valued with a PEG of 0.48. WDC earns a higher WallStSmart Score of 80/100 (A-).
ALNY
Strong Buy65
out of 100
Grade: B-
WDC
Exceptional Buy80
out of 100
Grade: A-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+86.4%
Fair Value
$2363.38
Current Price
$303.05
$2060.33 discount
Intrinsic value data unavailable for WDC.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Every $100 of equity generates 54 in profit
Revenue surging 96.4% year-over-year
Strong operational efficiency at 23.0%
Mega-cap, among the largest globally
Every $100 of equity generates 67 in profit
Keeps 55 of every $100 in revenue as profit
Strong operational efficiency at 37.0%
Revenue surging 45.5% year-over-year
Earnings expanding 482.9% YoY
Areas to Watch
0.0% earnings growth
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 37.6x book value
Premium valuation, high expectations priced in
Distress zone — elevated risk
Trading at 27.5x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on PEG Ratio, Return on Equity, Revenue Growth. Revenue growth of 96.4% demonstrates continued momentum. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : WDC
The strongest argument for WDC centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 55.3% and operating margin at 37.0%. Revenue growth of 45.5% demonstrates continued momentum.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, Debt/Equity, P/E Ratio. A P/E of 70.9x leaves little room for execution misses.
Bear Case : WDC
The primary concerns for WDC are P/E Ratio, Altman Z-Score, Price/Book.
Key Dynamics to Monitor
WDC carries more volatility with a beta of 2.20 — expect wider price swings.
ALNY is growing revenue faster at 96.4% — sustainability is the question.
WDC generates stronger free cash flow (978M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
WDC scores higher overall (80/100 vs 65/100), backed by strong 55.3% margins and 45.5% revenue growth. ALNY offers better value entry with a 86.4% margin of safety. Both earn "Exceptional Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Western Digital Corporation
TECHNOLOGY · COMPUTER HARDWARE · USA
Western Digital Corporation (WDC, commonly known as Western Digital or WD) is an American computer hard disk drive manufacturer and data storage company, headquartered in San Jose, California. It designs, manufactures and sells data technology products, including storage devices, data center systems and cloud storage services.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?